SAFETY AND PRELIMINARY EFFICACY OF MRNA-2752, A LIPID NANOPARTICLE ENCAPSULATING MRNAS ENCODING HUMAN OX40L/IL-23/IL-36g FOR INTRATUMORAL (ITU) INJECTION, AND DURVALUMAB (IV) IN TNBC, HNSCC, AND MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-073OA
A PHASE I STUDY OF HCW9218, A BIFUNCTIONAL TGFb ANTAGONIST/IL-15 PROTEIN COMPLEX, IN ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
SYNERGISTIC APPROACH TO OVERCOME THE SOLID TUMOR MICROENVIRONMENT OF MESOTHELIOMA WITH NATURAL KILLER CELL-FOCUSED IMMUNOTHERAPYJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
RESULTS OF A PHASE I TRIAL OF FT500, A FIRST-IN-CLASS, OFF-THE-SHELF, IPSC-DERIVED NK CELL THERAPY COMBINED WITH PD-1/PD-L1 CHECKPOINT BLOCKADE THERAPY AND IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
TRI-SPECIFIC KILLER ENGAGERS TARGET NATURAL KILLER CELLS TOWARDS MESOTHELIOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
PHASE I RESULTS OF FT516, AN OFF-THE-SHELF, IPSCDERIVED NK CELL THERAPY EXPRESSING A HIGHAFFINITY, NON-CLEAVABLE CD16 (HNCD16) COMBINED WITH AVELUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-072OA
NKTR-255+CETUXIMAB IN PATIENTS WITH SOLID TUMORS: INTERIM SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B DOSE-ESCALATION STUDYJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-102OA
RELATIONSHIP OF INFUSION DURATION AND DOSE TO SAFETY, EFFICACY AND PHARMACODYNAMICS: SECOND PART OF A PHASE 1-2 STUDY USING VSV-IFNβ-NIS (VV1) ONCOLYTIC VIRUS IN PATIENTS WITH REFRACTORY SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-101OA
PHASE 1 STUDY OF MRNA-2752, A LIPID NANOPARTICLE ENCAPSULATING MRNAS ENCODING HUMAN OX40L/IL-23/IL-36γ, FOR INTRATUMORAL (ITU) INJECTION plus /- DURVALUMAB IN ADVANCED SOLID TUMORS AND LYMPHOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-1019OA
A FIRST-IN-HUMAN PHASE I DOSE-ESCALATION TRIAL OF THE B7-H6/CD3 T-CELL ENGAGER BI 765049 ± EZABENLIMAB (BI 754091) IN PATIENTS WITH ADVANCED SOLID TUMORS EXPRESSING B7-H6JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-102OA
SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA-4157 IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH UNRESECTABLE SOLID TUMORS (KEYNOTE-603): AN UPDATEJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-1042PREAI
PRELIMINARY RESULTS OF AN ONGOING PHASE I TRIAL OF FT500, A FIRST-IN-CLASS, OFF-THE-SHELF, INDUCED PLURIPOTENT STEM CELL (IPSC) DERIVED NATURAL KILLER (NK) CELL THERAPY IN ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-1022PREAI
A FIRST-IN-HUMAN PHASE 1/2 OPEN LABEL TRIAL EVALUATING THE SAFETY, PHARMACOLOGY, AND PRELIMINARY EFFICACY OF VT1021 IN SUBJECTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-109PREAI
A PHASE 1 EVALUATION OF TEBOTELIMAB, A BISPECIFIC PD-1 X LAG-3 DART® MOLECULE, IN COMBINATION WITH MARGETUXIMAB IN PATIENTS WITH ADVANCED HER2+NEOPLASMSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-099PREAI
BDB001, A TOLL-LIKE RECEPTOR 7 AND 8 (TLR7/8) AGONIST, CAN BE SAFELY ADMINISTERED INTRAVENOUSLY AND SHOWS CLINICAL RESPONSES IN ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-092PREAI
nCirculating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCLINICAL CANCER RESEARCHIF10.22018-12-0346OAAI
Safety and activity of the IL-15/sIL-15Rα complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancerCLINICAL CANCER RESEARCHIF10.22018-09-010PRE
Safety and activity of the IL-15/sIL-15Rα complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancerCLINICAL CANCER RESEARCHIF10.22018-09-010PRE
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyCLINICAL CANCER RESEARCHIF10.22018-08-1475OAAI
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaCLINICAL CANCER RESEARCHIF10.22018-07-1563OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向